Nintedanib Stada

Nintedanib, the active ingredient in Nintedanib Stada, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain non‑small cell lung cancer indications.\n\nGNH India supplies Nintedanib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nintedanib is used to target fibrotic and oncologic pathways in several lung‑related conditions.\n\nIdiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression.\nSystemic sclerosis‑associated interstitial lung disease: limits fibrotic worsening and preserves respiratory capacity.\nNon‑small cell lung cancer (approved indications): inhibits tumor‑related angiogenesis and growth, contributing to disease control.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.\n\nCommon Side Effects:\n- Nausea\n- Diarrhea\n- Vomiting\n- Decreased appetite\n- Abdominal pain\n- Fatigue\n\nSerious or Rare Side Effects:\n- Elevated liver enzymes (ALT, AST)\n- Severe bleeding events\n- Cardiovascular complications (e.g., myocardial infarction)\n- Gastrointestinal perforation\n- Serious infections\n- Hypersensitivity reactions (e.g., rash, angioedema)

Before initiating therapy, clinicians should evaluate several safety considerations.\n\nMonitor liver function: obtain baseline tests and repeat periodically.\nAssess bleeding risk: avoid in patients with active hemorrhage or uncontrolled coagulopathy.\nAvoid strong CYP3A4 inhibitors: concomitant use may increase drug exposure.\nUse caution in cardiovascular disease: monitor for ischemic events.\nPregnancy: avoid use as safety data are lacking.\nStore at ambient temperature: keep in original container, protect from moisture and heat.

Nintedanib can interact with other medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations.\n- Anticoagulants (e.g., warfarin): increased risk of bleeding.\n- Antiplatelet agents (e.g., aspirin, clopidogrel): heightened bleeding tendency.\n\nModerate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly increase exposure.\n- CYP3A4 inducers (e.g., rifampicin): may reduce efficacy.\n- P‑gp substrates (e.g., digoxin): potential alteration of levels.